Want A Quick Inspection? Have Records Prepped And Don't Dilly-Dally When Asked For Documents, FDA Investigators Advise
This article was originally published in The Gray Sheet
When 86 percent of FDA domestic inspections are preannounced, it's difficult to imagine that manufacturers could be caught unprepared – yet many do not have the appropriate records ready for investigators when they knock on the front door. And an auditor's suspicion might be aroused when it takes a long time to retrieve a particular document, says investigator Laureen Geniusz, who recommends manufacturer transparency: "If the record is stored in a cave in Pennsylvania, let the investigator know that's why it’s going to take a while to get it."
You may also be interested in...
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?